Dr. Jean-Pierre Bizzari
Jean-Pierre Bizzari, M.D.,-Oncology
Dr. Bizzari holds a medical degree from the University of Nice (France) and trained as an oncolo-gist at the Pitie Salpetriere hospital in Paris.
He trained successively in Toronto (Ontario Cancer Institute – Canada) and Montreal (Mac Gill Cancer Center – Canada) before joining the pharmaceutical industry in 1983 as Head of the Oncology at the Institut de Recherches Internationales SERVIER (France). In 1993, he then joined Rhone-Poulenc Rorer as Vice President of Clinical Oncology, based in Paris and moved to Collegeville (PA – USA) in 1997.
With the merger of Rhone-Poulenc Rorer with HMR (to form Aventis), he was responsible for the Oncology Clinical Development at Aventis as Vice President. From April 2002 until September 2008, he was the Vice President of Clinical Development, Oncology, of Sanofi-Aventis in Malvern, PA.
Dr. Bizzari joined Celgene in 2008 (until 2016) as Executive Vice President, Clinical Development Oncology.
Some of Dr. Bizzari’s past accomplishments include, the Clinical Development of several anticancer agents such as:
–Fotemustine, ( melanoma, glioblastoma)
-Taxotere,( breast, NSC lung, prostate, H&N, gastric)
– Irinotecan, ( colon) – Gliadel,( glioblastoma)
– Eloxatin, ( colon) – Revlimid,( myeloma, MCL)
– Pomalyst ( myeloma) – Vidaza ( MDS)
– Abraxane ( NSC Lung, páncreas)
Dr. Bizzari has also been involved in the development of numerous compounds such as anti-angiogenics (VEGF-trap), gene therapy, vaccines and bio-reductive agents. He is a member of the Scientific Advisory Board of the French National Cancer Institute ( INCa) and a board member of the European Organisation of Research and Treatment of Cancer (EORTC)
Dr Bizzari is also on the Board of Director of Transgene SA, Halozyme Therapeutics,Nordic- Nanovector, Pieris, Onxeo and Compuge
He has published more than 70 articles in peer review journals and more than 160 abstracts in scientific congresses. Dr. Bizzari’s research interests include the methodology of clinical trials, and pk/pd analysis.